Nordic Group Launches LACRIFILL® Canalicular Gel for Dry Eye at 2024 AAO
Nordic Pharma, Inc., a subsidiary of Nordic Group BV, introduced LACRIFILL Canalicular Gel, an innovative therapy for dry eye, in the U.S. this April and is showcasing it to leading ophthalmologists at AAO 2024. This cross-linked hyaluronic acid gel, approved…
Tasso Survey: One in Three Patients Delay Blood Tests Due to Anxiety and Pain
Tasso, Inc., a leader in patient-centric blood collection solutions, recently surveyed over 600 U.S. adults aged 18 and older to explore their experiences and preferences regarding blood testing. The survey, titled Patient Preferences, Perceptions, and the Evolving Challenges of Ensuring…
Luminate Health Dominates Direct-to-Consumer Lab Testing Market
Luminate Health, a leader in healthcare technology for the clinical laboratory and diagnostics sector, is achieving remarkable success with its Direct-to-Consumer (DTC) lab testing platform. This innovative service allows commercial and hospital laboratories to connect directly with patients, enhancing accessibility…
Merck’s Clesrovimab Reduces RSV Disease and Hospitalization in Infants
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, recently shared encouraging outcomes from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab, a monoclonal antibody aimed at preventing respiratory syncytial virus (RSV) in infants. The findings were presented…
Prolucent Receives Strategic Investment from Northwell Holdings to Enhance Healthcare Workforce Management
Prolucent®, a leading provider of healthcare workforce optimization software and services, has announced a strategic investment from Northwell Holdings, the for-profit investment arm of Northwell Health, New York’s largest healthcare provider and private employer. This extended Series A funding follows…
Glaukos Reports Positive Phase 3 Results for Epioxa™, Meeting Primary Efficacy Endpoint
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases, has announced positive results from the second Phase 3 confirmatory trial for Epioxa™ (Epi-on). This next-generation corneal cross-linking…
Caracal and I2Pure Team Up to Launch New Disinfection Products
Caracal Products & Services and I2Pure have announced a collaboration to introduce new cutting-edge disinfection and antimicrobial products. Caracal, a certified Minority Business Enterprise and Tier 1 diversity spend supplier, provides a wide range of quality products and value-added services…
PursueCare Launches FDA-Authorized RESET® and RESET-O® for Addiction Treatment
PursueCare, a leader in virtual addiction treatment, has announced the launch of RESET® and RESET-O®, the first FDA-authorized prescription digital therapeutics for substance use disorder (SUD) and opioid use disorder (OUD). These innovative app-based therapies offer a self-guided 12-week cognitive…
Acadia Pharmaceuticals Gets Health Canada Approval for DAYBUE™ in Rett Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced that Health Canada has granted marketing authorization for DAYBUE™ (trofinetide) to treat Rett syndrome in patients aged two and older. This approval, under the Priority Review process, makes DAYBUE the first and only…
bit.bio Secures Landmark Patent Defense for opti-ox™ Cell Programming Technology
bit.bio, a leader in synthetic biology focused on coding human cells for innovative therapies, has successfully defended its foundational European patent for opti-ox. This groundbreaking technology allows for the deterministic forward programming of pluripotent stem cells (PSCs), including induced pluripotent…
Celltrion Reveals Two-Year Post-Hoc Analysis Results for Subcutaneous Infliximab (CT-P13 SC) in IBD Treatment
Celltrion has announced the two-year results of dose escalation therapy with subcutaneous infliximab (CT-P13 SC) at the United European Gastroenterology (UEG) Week 2024 in Vienna. A post-hoc analysis of the LIBERTY-CD (Crohn’s disease) and LIBERTY-UC (ulcerative colitis) studies indicates that…
FDA Approves Novocure’s Optune Lua® for Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) has announced that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for use alongside PD-1/PD-L1 inhibitors or docetaxel. This treatment is intended for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have…